Akero Therapeutics, Inc. (AKRO): Price and Financial Metrics
GET POWR RATINGS... FREE!
AKRO Stock Price Chart Interactive Chart >
AKRO Price/Volume Stats
| Current price | $8.84 | 52-week high | $30.53 |
| Prev. close | $8.28 | 52-week low | $7.88 |
| Day low | $8.01 | Volume | 216,000 |
| Day high | $8.87 | Avg. volume | 233,301 |
| 50-day MA | $11.78 | Dividend yield | N/A |
| 200-day MA | $18.63 | Market Cap | 309.60M |
Akero Therapeutics, Inc. (AKRO) Company Bio
Akero Therapeutics, Inc. operates as a biotechnology company. The firm specializes in transformational treatments for non-alcoholic steatohepatitis (NASH) and other serious metabolic diseases. The company was founded by Jonathan Young and Timothy Rolph on January 24, 2017 and is headquartered in South San Francisco, CA.
Latest AKRO News From Around the Web
Below are the latest news stories about Akero Therapeutics Inc that investors may wish to consider to help them evaluate AKRO as an investment opportunity.
Akero Therapeutics Reports Fourth Quarter and Full Year 2021 Financial ResultsAkero Remains on Track to Report Phase 2b HARMONY Study Results in the Third Quarter of This Year Akero Remains on Track to Report Phase 2b HARMONY Study Results in the Third Quarter of This Year |
Analysts Offer Insights on Healthcare Companies: Karyopharm Therapeutics (KPTI) and Akero Therapeutics (AKRO)There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Karyopharm Therapeutics (KPTI – Research Report) and Akero Therapeutics (AKRO – Research Report) with bullish sentiments. Karyopharm Therapeutics (KPTI) H.C. Wainwright analyst Edward White maintained a Buy rating on Karyopharm Therapeutics today and set a price target of $26.00. The company's shares closed last Wednesday at $9.13. According to TipRanks. |
Akero finishes enrollment in phase 2b trial of efruxifermin in liver diseaseAkero Therapeutics (AKRO -0.2%) completed enrollment in a phase 2b study, dubbed HARMONY, evaluating efruxifermin (EFX) to treat non-alcoholic steatohepatitis (NASH). "Our confidence in EFX’s potential is based on Phase 2a data that showed substantial rates of fibrosis regression after only 16 weeks of treatment. We believe the larger Phase 2b HARMONY... |
Akero Therapeutics Completes Enrollment of Phase 2b HARMONY Study in Pre-Cirrhotic NASH PatientsSOUTH SAN FRANCISCO, Calif., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that it has completed enrollment of the Phase 2b HARMONY study of efruxifermin (EFX), a novel FGF21 analog, for the treatment of non-alcoholic steatohepatitis (NASH). |
Is Akero Therapeutics, Inc. (AKRO) Outperforming Other Medical Stocks This Year?Here is how Akero Therapeutics, Inc. (AKRO) and Butterfly Network, Inc. (BFLY) have performed compared to their sector so far this year. |
AKRO Price Returns
| 1-mo | -15.73% |
| 3-mo | -50.14% |
| 6-mo | -58.42% |
| 1-year | -66.23% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -58.20% |
| 2021 | -18.02% |
| 2020 | 16.24% |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...